
The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Senate Legislative Services. The keyword, summary, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

SB 253 Engrossed

DIGEST
2026 Regular Session

McMath

Proposed law provides that no professional or occupational licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from a FDA-registered 503B facility or a 503A compounding pharmacy that buys its active pharmaceutical ingredients from an FDA-registered manufacturer.

Proposed law requires the prescribing provider to ensure any peptides prescribed pursuant to proposed law are not on the FDA's prohibited compounding list.

Proposed law provides that no professional or occupational licensing board shall prohibit a state-licensed compounding pharmacy from compounding and dispensing peptides, provided that the peptide is not included in the FDA's list of substances prohibited for compounding or the FDA Category 2 list of bulk drug substances.

Proposed law provides that once a peptide is removed from the FDA Category 2 list, a state-licensed compounding pharmacy may compound the peptide provided the active pharmaceutical ingredient is obtained from an FDA-registered manufacturer and the pharmacy otherwise complies with all applicable federal and state compounding laws and regulations.

Effective August 1, 2026.

(Adds R.S. 37:23.5)

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Extends provisions of proposed law to compounding pharmacies.